GRAL NASDAQ
Credit Risk of going bust: lower than 53% of companies Debt: 1.4% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.35 (down 99.7%), GRAIL Inc. would be worth roughly what it owes.
Total debt $91.3M against a stock market value of $6.25B.
Distance to default 5.44 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $45.7M (short-term plus half of long-term), stock volatility 85.4%; Altman Z'' -2.40. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Menlo Park, CA 94025
US
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| SUMME GREGORY L | A-Award | 237 | $135.46 | 2026-10-15 |
| CHASE WILLIAM J | A-Award | 153 | $135.46 | 2026-10-15 |
| Ofman Joshua J. | S-Sale | 400 | $133.12 | 2026-10-15 |
| Ofman Joshua J. | S-Sale | 1,000 | $134.38 | 2026-10-15 |
| Ofman Joshua J. | S-Sale | 3,400 | $135.44 | 2026-10-15 |